Effect of Antibiotic Susceptibility and CYP3A4/5 and CYP2C19 Genotype on the Outcome of Vonoprazan-Containing Helicobacter pylori Eradication Therapy
出版年份 2020 全文链接
标题
Effect of Antibiotic Susceptibility and CYP3A4/5 and CYP2C19 Genotype on the Outcome of Vonoprazan-Containing Helicobacter pylori Eradication Therapy
作者
关键词
-
出版物
Antibiotics-Basel
Volume 9, Issue 10, Pages 645
出版商
MDPI AG
发表日期
2020-09-28
DOI
10.3390/antibiotics9100645
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Role of Vonoprazan in Helicobacter pylori Eradication Therapy in Japan
- (2019) Mitsushige Sugimoto et al. Frontiers in Pharmacology
- Systematic review with meta-analysis: Vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori
- (2018) Min Li et al. HELICOBACTER
- Randomized trial of vonoprazan-based versus proton-pump inhibitor-based third-line triple therapy with sitafloxacin for Helicobacter pylori
- (2018) Soichiro Sue et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Review: A Japanese population-based meta-analysis of vonoprazan versus PPI for Helicobacter pylori eradication therapy: Is superiority an illusion?
- (2017) Shou Quan Dong et al. HELICOBACTER
- Efficacy of the Kyoto Classification of Gastritis in Identifying Patients at High Risk for Gastric Cancer
- (2017) Mitsushige Sugimoto et al. INTERNAL MEDICINE
- Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype
- (2016) T. Kagami et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Successful eradication of Helicobacter pylori infection with vonoprazan-based triple therapy after failure of PPI-based triple therapy
- (2016) Kousaku Kawashima et al. DIGESTIVE AND LIVER DISEASE
- Efficacy of vonoprazan-based second-line Helicobacter pylori eradication therapy in patients for whom vonoprazan-based first-line treatment failed
- (2016) Yasumi Katayama et al. GUT
- Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy forHelicobacter pylorieradication: a phase III, randomised, double-blind study
- (2016) Kazunari Murakami et al. GUT
- Vonoprazanversusconventional proton pump inhibitor-based triple therapy as first-line treatment againstHelicobacter pylori: A multicenter retrospective study in clinical practice
- (2016) Satoki Shichijo et al. Journal of Digestive Diseases
- Comparison of vonoprazan and proton pump inhibitors for eradication of Helicobacter pylori
- (2016) Satoshi Shinozaki et al. KAOHSIUNG JOURNAL OF MEDICAL SCIENCES
- Analysis of the cost-effectiveness of using vonoprazan–amoxicillin–clarithromycin triple therapy for first-line Helicobacter pylori eradication
- (2016) Yusaku Kajihara et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- In vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker
- (2016) Hitomi Yamasaki et al. XENOBIOTICA
- Safety and efficacy of Vonoprazan-based triple therapy against Helicobacter pylori infection: A single-center experience with 1118 patients
- (2016) Daisuke Fukuda et al. Therapeutic Advances in Gastroenterology
- HighHelicobacter pyloricure rate with sitafloxacin-based triple therapy
- (2015) M. Sugimoto et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Efficacy of 10-day Sitafloxacin-Containing Third-Line Rescue Therapies forHelicobacter pyloriStrains Containing thegyrAMutation
- (2015) Hideki Mori et al. HELICOBACTER
- Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole
- (2014) S. Sahara et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- The Role of Pharmacogenetics in the Disposition of and Response to Tacrolimus in Solid Organ Transplantation
- (2013) Dennis A. Hesselink et al. CLINICAL PHARMACOKINETICS
- Multi-center randomized controlled study to establish the standard third-line regimen for Helicobacter pylori eradication in Japan
- (2013) Kazunari Murakami et al. JOURNAL OF GASTROENTEROLOGY
- Sitafloxacin-based third-line rescue regimens forHelicobacter pyloriinfection in Japan
- (2013) Takahisa Furuta et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Association of Helicobacter pylori dupA With the Failure of Primary Eradication
- (2012) Seiji Shiota et al. JOURNAL OF CLINICAL GASTROENTEROLOGY
- Effect of CYP3A and ABCB1 Single Nucleotide Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Calcineurin Inhibitors: Part I
- (2010) Christine E. Staatz et al. CLINICAL PHARMACOKINETICS
- 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine Monofumarate (TAK-438), a Novel and Potent Potassium-Competitive Acid Blocker for the Treatment of Acid-Related Diseases
- (2010) Y. Hori et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs
- (2010) D Wang et al. PHARMACOGENOMICS JOURNAL
- Virulence factor genotypes of Helicobacter pylori affect cure rates of eradication therapy
- (2009) Mitsushige Sugimoto et al. ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started